Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Windtree Therapeutics ( (WINT) ) has issued an announcement.
On August 5, 2025, Windtree Therapeutics announced interim data from its SEISMiC C Phase 2 study evaluating istaroxime in SCAI Stage C cardiogenic shock patients. The study, which includes sites in the U.S., Europe, and Latin America, showed that istaroxime, when added to current inotropes and vasopressors, maintained a consistent safety profile and physiological improvements similar to previous trials. With no new safety concerns and promising hemodynamic results, the company is confident in advancing to a global Phase 3 trial, potentially offering advantages over existing therapies for severe cardiogenic shock.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.
Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Windtree Therapeutics, Inc. is a diversified company with several divisions, including a cryptocurrency treasury strategy and two promising therapeutic pipelines for which the company is actively seeking long-term development partners.
Average Trading Volume: 10,924,880
Technical Sentiment Signal: Sell
Current Market Cap: $17.2M
Learn more about WINT stock on TipRanks’ Stock Analysis page.